Key Highlights

● Clover Health filed an 8-K/A on September 25, 2026 solely to correct an administrative error in the title of a press release exhibit, restating that former U.S. Senator Robert Torricelli and physician Dr. Brian J. Miller joined the board effective September 22, 2026.

● Torricelli takes the Class I board seat and joins the Audit Committee, while Dr. Miller, a Johns Hopkins hospitalist and MedPAC commissioner, takes the Class III seat and joins the Clinical Committee.

● The two appointments expand Clover Health's board from seven to nine directors, with each new director receiving a pro-rated annual cash retainer plus a restricted stock unit award valued at $200,000, prorated through December 31, 2026.

● CEO Andrew Toy and Executive Chairperson Vivek Garipalli both offered supportive comments on the appointments, though the filing does not disclose why the two board seats had been vacant or whether either director will stand for election at the next annual meeting.

Clover Health Investments, Corp. (NASDAQ:CLOV) filed an amended 8-K/A on September 25, 2026 to fix a clerical error in an earlier disclosure, while restating that it has added two new independent directors, former U.S. Senator Robert Torricelli and physician Dr. Brian J. Miller, to its board effective September 22, 2026.

What the Amendment Actually Changes

The 8-K/A itself is narrow in scope. It states plainly: "The sole purpose of this Amendment is to make an administrative correction to the title of the press release filed as Exhibit 99.1 under Item 9.01." In other words, the underlying news, two new directors joining the board, was already disclosed in an original 8-K filed the day before, on September 24, 2026; this amendment only corrects the heading on the attached press release. The substantive Item 5.02 disclosure about the appointments is otherwise unchanged.

The New Directors and Their Roles

Torricelli, who represented New Jersey for 20 years in the U.S. House and Senate and served on the Senate Finance Committee with a focus on healthcare financing, joins Clover's Class I board seat and will sit on the Audit Committee. He has served on the board of Clover's insurance subsidiaries since 2022 and currently leads Rosemont Associates, a Business strategy firm, and Woodrose Properties, a real estate development company. In the filing's attached press release, Torricelli is quoted saying: "Through my service on Clover's insurance Subsidiary board, I have seen the Company's commitment to meeting those challenges with an ambitious vision and a practical, technology-driven approach."

Dr. Miller, a practicing hospitalist at Johns Hopkins Hospital and an Associate Professor of Medicine at Johns Hopkins University School of Medicine, takes the Class III seat and joins the Clinical Committee. He is board-certified in internal medicine and preventive medicine, serves as Vice Chairman of the Board of Trustees for the North Carolina State Health Plan, and sits as a Commissioner on the federal Medicare Payment Advisory Commission (MedPAC). He is quoted in the release saying: "Medicare needs models that can improve both convenience and quality for consumers, increase efficiency, and generate savings without adding burden."

Board Expansion and Compensation

The two appointments expand Clover Health's board from seven to nine directors, filling vacancies the company had previously disclosed it intended to fill. Under the standard non-employee director compensation arrangement referenced in the filing, each new director will receive a pro-rated annual cash retainer for board and committee service, plus a restricted stock unit award valued at $200,000, itself prorated based on the number of days served through December 31, 2026. Both directors have also signed the company's standard indemnification agreement, a customary protection extended to board members.

CEO Andrew Toy is quoted in the press release saying the appointments strengthen the board's ability to "execute with discipline, grow responsibly, and build lasting value," while co-founder and Executive Chairperson Vivek Garipalli called the new directors "special individuals who understand" healthcare from "fundamentally different vantage points."

What the Filing Does Not Say

The 8-K/A does not disclose any search process, term length details beyond committee assignments, or whether either new director will stand for election at Clover's next annual meeting. It also does not identify who previously held the two vacant board seats or why they became vacant.

Proxy Disclosures to Watch for on the Expanded Board

Investors should watch for Clover Health's next proxy statement, which should disclose whether Torricelli and Miller stand for Shareholder election and provide full biographical and compensation detail; any further board committee reassignments tied to the expanded nine-member board; and continued disclosure, if any, tied to the pro-rated 2026 compensation once the year closes.